July 23, 2014 5:26 PM ET

Biotechnology

Company Overview of Bioenvision, Inc.

Company Overview

As of October 23, 2007, Bioenvision, Inc. was acquired by Genzyme Corp. Bioenvision, Inc., a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy. The company is also developing Evoltra for use in combination with other age...

345 Park Avenue

41st Floor

New York, NY 10154

United States

Founded in 1996

32 Employees

Phone:

212-750-6700

Fax:

212-750-6777

Key Executives for Bioenvision, Inc.

Bioenvision, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
MMR Life Sciences Group, Inc. United States
Synthecon, Inc. United States
Omniox Inc. United States
BioPharm Solutions, Inc. United States
Phoenix Pharmacologics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bioenvision, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.